Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Impact of cell culture transition on adipose-derived mesenchymal stromal cells: Multi-omics analysis of small- vs large-scale production.

Galera MR., Oikonomou A., Elsborg JD., Harth L., Fischer-Nielsen A., Løvendorf MB.

Clinical Trial on Immune Modulation, published in Mol Ther Methods Clin Dev (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Mol Ther Methods Clin Dev (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40687374
PMCID
PMC12270734
DOI
10.1016/j.omtm.2025.101512

Abstract (original English)

Mesenchymal stromal cells (MSCs) are being tested in numerous clinical trials, yet the limited progression of these trials to advanced stages indicates unresolved translational challenges. Expanding MSCs is a critical step in most therapeutic applications, and bioreactor-based culture offers large-scale production compared to monolayer cultures. Nevertheless, since MSCs sense their microenvironment, it is crucial to understand how these systems affect their properties. We expanded human adipose-derived mesenchymal stromal cells (AD-MSCs) from the same donors in both small- and large-scale platforms. Bulk-RNA sequencing (RNA-seq) and mass spectrometry analysis demonstrated that small-scale culture had a broader range of differentially expressed genes (DEGs) and proteins within immunomodulatory, cell migration, and cell adhesion pathways. In contrast, the large-scale culture showed a lower amount of DEGs and proteins associated mainly with extracellular matrix synthesis. Our findings demonstrate that expansion platforms significantly impact MSCs' properties, highlighting the need to optimize expansion conditions to obtain high cell yield without compromising MSCs' attributes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research